ACG Wealth’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $2.99M | Sell |
11,213
-1,615
| -13% | -$343K | 0.68% | 40 |
|
|
2022
Q2 | $2.62M | Sell |
12,828
-390
| -3% | -$79.7K | 0.53% | 52 |
|
|
2022
Q1 | $2.78M | Sell |
13,218
-8,864
| -40% | -$1.93M | 0.53% | 54 |
|
|
2021
Q4 | $5.3M | Sell |
22,082
-5,891
| -21% | -$1.51M | 0.75% | 38 |
|
|
2021
Q3 | $7.92M | Sell |
27,973
-265
| -0.9% | -$86.9K | 1.04% | 24 |
|
|
2021
Q2 | $9.78M | Buy |
28,238
+6,269
| +29% | +$1.9M | 1.24% | 16 |
|
|
2021
Q1 | $6.15M | Buy |
21,969
+1,268
| +6% | +$342K | 0.82% | 30 |
|
|
2020
Q4 | $5.07M | Sell |
20,701
-203
| -1% | -$52.4K | 0.7% | 41 |
|
|
2020
Q3 | $5.93M | Buy |
20,904
+1,042
| +5% | +$291K | 0.89% | 25 |
|
|
2020
Q2 | $5.31M | Sell |
19,862
-436
| -2% | -$131K | 0.87% | 29 |
|
|
2020
Q1 | $6.42M | Sell |
20,298
-586
| -3% | -$178K | 1.2% | 14 |
|
|
2019
Q4 | $6.2M | Sell |
20,884
-608
| -3% | -$169K | 0.92% | 27 |
|
|
2019
Q3 | $5M | Buy |
21,492
+1,465
| +7% | +$341K | 0.74% | 35 |
|
|
2019
Q2 | $4.68M | Buy |
20,027
+7,219
| +56% | +$1.67M | 0.63% | 44 |
|
|
2019
Q1 | $3.03M | Buy |
12,808
+1,773
| +16% | +$558K | 0.41% | 60 |
|
|
2018
Q4 | $3.32M | Buy |
11,035
+3,572
| +48% | +$1.14M | 0.51% | 51 |
|
|
2018
Q3 | $2.64M | Buy |
7,463
+328
| +5% | +$113K | 0.35% | 68 |
|
|
2018
Q2 | $2.07M | Sell |
7,135
-536
| -7% | -$151K | 0.31% | 73 |
|
|
2018
Q1 | $2.1M | Buy |
7,671
+277
| +4% | +$86K | 0.32% | 81 |
|
|
2017
Q4 | $2.36M | Sell |
7,394
-286
| -4% | -$91.8K | 0.35% | 79 |
|
|
2017
Q3 | $2.4M | Buy |
7,680
+65
| +0.9% | +$19.2K | 0.42% | 65 |
|
|
2017
Q2 | $2.07M | Buy |
7,615
+122
| +2% | +$32.3K | 0.34% | 83 |
|
|
2017
Q1 | $2.05M | Sell |
7,493
-13
| -0.2% | -$3.68K | 0.38% | 81 |
|
|
2016
Q4 | $2.13M | Sell |
7,506
-576
| -7% | -$171K | 0.45% | 64 |
|
|
2016
Q3 | $2.53M | Buy |
8,082
+209
| +3% | +$61.9K | 0.54% | 55 |
|
|
2016
Q2 | $1.9M | Buy |
7,873
+42
| +0.5% | +$11.1K | 0.42% | 71 |
|
|
2016
Q1 | $2.04M | Sell |
7,831
-91
| -1% | -$24K | 0.46% | 65 |
|
|
2015
Q4 | $2.43M | Buy |
7,922
+496
| +7% | +$143K | 0.54% | 56 |
|
|
2015
Q3 | $2.17M | Buy |
7,426
+799
| +12% | +$264K | 0.58% | 52 |
|
|
2015
Q2 | $2.68M | Sell |
6,627
-156
| -2% | -$62.6K | 0.67% | 43 |
|
|
2015
Q1 | $2.86M | Sell |
6,783
-463
| -6% | -$182K | 0.76% | 39 |
|
|
2014
Q4 | $2.46M | Buy |
7,246
+36
| +0.5% | +$11.6K | 0.66% | 44 |
|
|
2014
Q3 | $2.38M | Sell |
7,210
-7,354
| -50% | -$2.42M | 0.67% | 49 |
|
|
2014
Q2 | $4.59M | Buy |
14,564
+6,885
| +90% | +$2.07M | 0.87% | 41 |
|
|
2014
Q1 | $2.35M | Sell |
7,679
-4,023
| -34% | -$1.28M | 0.7% | 40 |
|
|
2013
Q4 | $3.27M | Buy |
11,702
+552
| +5% | +$143K | 0.84% | 34 |
|
|
2013
Q3 | $2.68M | Sell |
11,150
-1,725
| -13% | -$386K | 1.11% | 21 |
|
|
2013
Q2 | $2.77M | Buy |
+12,875
| New | +$2.75M | 1.08% | 20 |
|
Other funds holding BIIB
ACG Wealth's BIIB Position: Q3 2022 in Review
ACG Wealth reduced its Biogen (BIIB) stake by 13% in Q3 2022, selling an estimated $343K and leaving 11,213 shares worth $2.99M. The position accounts for 0.68% of the portfolio, ranked #40.
ACG Wealth first reported a position in BIIB in Q2 2013 and has held it in 38 quarters since. The position peaked at $9.78M in Q2 2021. 986 funds tracked by Wall St. Rank hold BIIB as of Q3 2022.
- ACG Wealth held 11,213 shares of Biogen worth $2.99M as of Q3 2022.
- ACG Wealth sold 1,615 Biogen shares in Q3 2022, an estimated $343K.
- Biogen made up 0.68% of ACG Wealth's portfolio in Q3 2022, its #40 holding.
- ACG Wealth first reported a position in Biogen in Q2 2013 and has held it in 38 quarters since.
- ACG Wealth's Biogen position peaked at $9.78M in Q2 2021.
- 986 funds tracked by Wall St. Rank held Biogen as of Q3 2022.
Based on ACG Wealth's 13F filing for Q3 2022, filed 3 Nov 2022.